University of Groningen Development and Application of Novel Scaffolds In

Total Page:16

File Type:pdf, Size:1020Kb

University of Groningen Development and Application of Novel Scaffolds In University of Groningen Development and application of novel scaffolds in drug discovery Boltjes, André DOI: 10.33612/diss.98161351 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2019 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Boltjes, A. (2019). Development and application of novel scaffolds in drug discovery: the MCR approach. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.98161351 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 11-10-2021 DEVELOPMENT AND APPLICATION OF NOVEL SCAFFOLDS IN DRUG DISCOVERY The MCR approach André Boltjes The research described in this thesis was carried out at the Department of Drug Design (Groningen Research Institute of Pharmacy, University of Groningen, The Netherlands) and was financially supported by the University of Groningen. Printing of this thesis was financially supported by the University Library and the Graduate School of Science, Faculty of Science and Engineering, University of Groningen, The Netherlands ISBN: 978-94-034-2005-9 (printed version) ISBN: 978-94-034-2004-2 (electronic version) Printing: Ipskamp printing, Enschede Cover design: André Boltjes Cover Graphics: By pikisuperstar Source: Freepik Copyright © 2019 André Boltjes. All rights are reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without the prior permission in writing of the author. Development and application of novel scaffolds in Drug Discovery The MCR approach Proefschrift ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op vrijdag 29 november 2019 om 14.30 uur door André Boltjes geboren op 10 april 1984 te Wieringermeer Promotores Prof. dr. A.S.S. Dömling Prof. dr. F.J. Dekker Beoordelingscommissie Prof. dr. R.V.A Orru Prof. dr. G.J. Poelarends Prof. dr. ir. A.J. Minnaard Table of Contents CHAPTER 1 GENERAL INTRODUCTION 1 CHAPTER 2 FRAGMENT BASED LIBRARY GENERATION FOR 11 THE DISCOVERY OF A PEPTIDOMIMETIC P53-MDM4 INHIBITOR CHAPTER 3 UGI MULTICOMPONENT APPROACH TO 35 SYNTHESIZE SCHISTOSOMIASIS DRUG PRAZIQUANTEL CHAPTER 4 UGI 4-CR SYNTHESIS OF γ- AND δ-LACTAMS 51 PROVIDING NEW ACCESS TO DIVERSE ENZYME INTERACTIONS, A PDB ANALYSIS CHAPTER 5 Gd-TEMDO: DESIGN, SYNTHESIS AND MRI 75 APPLICATION CHAPTER 6 THE GROEBKE-BLACKBURN-BIENAYMÉ 97 REACTION CHAPTER 7 DIVERSE ONE-POT SYNTHESIS OF ADENINE 189 MIMETICS FOR BIOMEDICAL APPLICATIONS CHAPTER 8 SUMMARY AND DISCUSSION 213 SAMENVATTING NEDERLANDSE SAMENVATTING 223 APPENDIX ACKNOWLEDGEMENTS 231 LIST OF PUBLICATIONS ABOUT THE AUTHOR Chapter 1 Introduction MCR introduction, Perspective and Outline Chapter 1 Multicomponent reactions Multicomponent reactions (MCRs) are a special class of chemical transforma- tions, which produce complex scaffolds in a single step by employing three or more starting materials, in which most of the atoms are present in the final prod- uct.1 This type of chemistry can be classified as a domino reaction. Similar to polymer chemistry, MCRs proceed through a cascade of intermediate reactions, however, yielding a complex but small molecule. The first example of a MCR reaction is the Strecker amino acid synthesis, developed almost 170 years ago in 1850. The Strecker reaction is a 3-component reaction (3-CR) between an alde- hyde or ketone, ammonia and potassium cyanide and yields an α-aminonitrile, subsequent hydrolysis gives access to synthetic α-amino acids (Scheme 1).2 The high atom economy, efficiency, convergent nature and very high bond forming index of MCR reactions make this class extremely useful for drug exploration.3 O R + NH3 + KCN R H H2N COOH Scheme 1. The Strecker amino acid synthesis. MCRs are often considered to be complex, because the formation of the final products proceed via a number of intermediate steps. In order to understand the complex nature of MCRs, a breakdown of the reaction into intermediate steps could aid in comprehension of the underlying mechanism. Difference in reactiv- ity of each of the individual components is the driving force behind selective re- actions, resulting in a predefined order in which each component will react. The most common studied and therefore well-developed early type of MCRs evolve around the reactivity of imine groups, usually obtained through reacting carbon- yl compounds with amines. The resulting imines or Schiff bases are electrophiles and can react via electrophilic addition to for example α-methylene carbonyls in the Mannich 3-CR, to β-ketoesters in the Biginelli 3-CR, to boronates (from boronic acids) in the Petasis 3-CR and many other reactions, described in scheme 2.4-8 The formation of the Schiff base is performed in the presence of the third component, the electrophile, in a one-pot fashion, which in practice comes down to adding all the reactants together in a suitable solvent and stir the multicom- ponent reaction, often under ambient conditions. The selective order generally allows for a clean reaction with little byproducts and high conversion towards a single product. 1 Introduction O R1 R2 NH Strecker + 2 + HCN R3 R3 N CN R1 R2 H 1 R3 R4 O O H O Mannich + N + R1 R R R5 N R6 R3 R4 1 2 R6 R2 R5 O R1 O O O O Hantsch + NH2 + 2 R2 R1 H N R2 O R O O 3 Staudinger + NH2 + R2 R3 N R1 H Cl R2 R1 R R O H 1 4 Petasis + N + B(OH)2 R H R2 R3 R4 N 1 R2 R3 O Ar O O O O EtO NH Biginelli + + Ar H H2N NH2 EtO H3C N O H Scheme 2. Overview of the most common MCR 3-CR of amines, carbonyl compounds and nucleophiles. In 1920, Passerini discovered the first isocyanide based MCR reaction (IMCR) and involves an isocyanide, an oxo component and a nucleophile.9 The carbene like properties of the isocyanide group allow for some very interesting transfor- mations, as this functional group can behave as nucleophile and then as electro- phile at the same atom, resulting to the so-called α-adduct.10 The IMCR subclass has complemented the field of MCR due to its versatile reactivity, variability and scaffolds and is currently the most widely used/applied type of MCR. Neverthe- less it took roughly 40 years until more developments were made in this field, which can be attributed to the obnoxious smell of the isocyanides. The smell is 2 Chapter 1 considered unpleasant, even in such a way that the US government investigated the use of isocyanides as non-lethal chemical weapons.11 The considered ‘con- straint’ is limited to the liquid isocyanides, as higher molecular weight isocya- nides are often solid and have little to no smell. Regardless of this fact, the result is poor commercial availability, which is not necessarily problematic as isocya- nides can readily be prepared from primary amines or aldehydes in one or two steps.12-14 O O O R1 R2 H Passerini-3CR + + NC N R4 R3 O R4 1920 R1 R2 R3 OH O O R R O O 1 2 H + NH2 + + NC N Ugi-4CR R3 R5 R4 N R5 1959 R1 R2 R4 OH R3 O H R1 R2 O H NC N R4 Ugi-3CR + N + R N R R R5 5 1959 R1 R2 3 4 O R3 R1 R2 R5 O H + + + NC R3 N Ugi Tetrazole-4CR N HN3 N R R R5 N 1959 R1 R2 3 4 R4 N N R O Ts 2 N N + NH + Van Leusen-3CR R 2 1977 R H 2 R NC 1 3 R1 R3 HN R2 Groebke Blackburn O 5- N + + NC N 6- R2 5- Bienaymè-3CR R1 R1 H NH2 6- 1998 N Scheme 3. Some of the well-known IMCRs A considerable amount of pioneering work with IMCRs was performed by Ugi in the late 1950s. The Ugi-4CR is defined as the reaction of an amine with an aldehyde or ketone, an isocyanide and a carboxylic acid (Scheme 3).15 The limits of IMCRs were explored by Ivar Ugi and since the introduction of the Ugi 4-CR, many new IMCR reactions have found their way to the nowadays well accept- 3 Introduction ed field of MCR chemistry. The work described in this thesis is based on drug design, utilizing the Ugi reaction and several variations of the Ugi reaction to synthesize drug like compounds and medical probes. 1 Drug discovery and MCR. Identification of biochemical pathways related to a disease and the intervention of potential targets is the first step in the discovery of new medicines.
Recommended publications
  • A One Pot Synthesis of Novel Bioactive Tri-Substitute-Condensed
    RESEARCH ARTICLE A One Pot Synthesis of Novel Bioactive Tri- Substitute-Condensed-Imidazopyridines that Targets Snake Venom Phospholipase A2 Nirvanappa C. Anilkumar1, Mahalingam S. Sundaram2, Chakrabhavi Dhananjaya Mohan3, Shobith Rangappa4, Krishna C. Bulusu5, Julian E. Fuchs5, Kesturu S. Girish2,6, Andreas Bender5, Basappa1*, Kanchugarakoppal S. Rangappa3* 1 Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, Central College campus, Palace Road, Bangalore-560 001, Karnataka, India, 2 Department of Studies in Biochemistry, University of Mysore, Mysore-570 006, Karnataka, India, 3 Department of Studies in Chemistry, University of Mysore, Mysore-570 006, Karnataka, India, 4 Frontier Research Center for Post-genome Science and Technology Hokkaido University, Sapporo, 060–0808, Japan, 5 Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW, Cambridge, United Kingdom, 6 Department of Studies and Research in Biochemistry, Tumkur University, Tumkur-572 103, Karnataka, India * [email protected] (KSR); [email protected] (B) OPEN ACCESS Citation: Anilkumar NC, Sundaram MS, Mohan CD, Abstract Rangappa S, Bulusu KC, Fuchs JE, et al. (2015) A One Pot Synthesis of Novel Bioactive Tri-Substitute- Drugs such as necopidem, saripidem, alpidem, zolpidem, and olprinone contain nitrogen- Condensed-Imidazopyridines that Targets Snake containing bicyclic, condensed-imidazo[1,2-α]pyridines as bioactive scaffolds. In this work, Venom Phospholipase A2. PLoS ONE 10(7): e0131896. doi:10.1371/journal.pone.0131896 we report a high-yield one pot synthesis of 1-(2-methyl-8-aryl-substitued-imidazo[1,2-α] in silico Editor: Luis Eduardo M Quintas, Universidade pyridin-3-yl)ethan-1-onefor the first-time.
    [Show full text]
  • In Silico Screening of Novel Α1-GABAA Receptor Pams Towards Schizophrenia Based on Combined Modeling Studies of Imidazo [1,2-A]-Pyridines
    International Journal of Molecular Sciences Article In Silico Screening of Novel α1-GABAA Receptor PAMs towards Schizophrenia Based on Combined Modeling Studies of Imidazo [1,2-a]-Pyridines Xiaojiao Zheng 1, Chenchen Wang 1, Na Zhai 1, Xiaogang Luo 1,2, Genyan Liu 1,* and Xiulian Ju 1,* 1 Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, China; [email protected] (X.Z.); [email protected] (C.W.); [email protected] (N.Z.); [email protected] (X.L.) 2 School of Materials Science and Engineering, Zhengzhou University, No. 100 Science Avenue, Zhengzhou 450001, China * Correspondence: [email protected] (G.L.); [email protected] (X.J.) Abstract: The ionotropic GABAA receptor (GABAAR) has been proven to be an important target of atypical antipsychotics. A novel series of imidazo [1,2-a]-pyridine derivatives, as selective positive allosteric modulators (PAMs) of α1-containing GABAARs with potent antipsychotic activities, have been reported recently. To better clarify the pharmacological essentiality of these PAMs and explore novel antipsychotics hits, three-dimensional quantitative structure–activity relationships (3D-QSAR), molecular docking, pharmacophore modeling, and molecular dynamics (MD) were performed on 33 imidazo [1,2-a]-pyridines. The constructed 3D-QSAR models exhibited good predictive abilities. The dockings results and MD simulations demonstrated that hydrogen bonds, π–π stackings, and hydrophobic interactions play essential roles in the binding of these novel PAMs in the GABAAR Citation: Zheng, X.; Wang, C.; Zhai, binding pocket. Four hit compounds (DS01–04) were then screened out by the combination of N.; Luo, X.; Liu, G.; Ju, X.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0158983 A1 Bascomb Et Al
    US 2011 O158983A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0158983 A1 Bascomb et al. (43) Pub. Date: Jun. 30, 2011 (54) COMPOSITIONS AND METHODS FOR A63L/4045 (2006.01) MUCOSITIS AND ONCOLOGY THERAPES A638/00 (2006.01) A 6LX 3/57 (2006.01) (76) Inventors: Newell Bascomb, Chester Springs, A 6LX 3L/2197 (2006.01) PA (US); John Maki, Mendham, A63L/506 (2006.01) NJ (US); Fredric S. Young, Los A63L/454 (2006.01) Altos, CA (US) A6II 3/69 (2006.01) A63L/352 (2006.01) (21) Appl. No.: 12/921,145 A63L/382 (2006.01) A63L/337 (2006.01) (22) PCT Fled: Mar. 5, 2009 A6II 3/426 (2006.01) A63L/437 (2006.01) A63/675 (2006.01) S371 (c)(1), A63L/4375 2006.O1 (2), (4) Date: Mar. 14, 2011 A63L/435 308: Related U.S. Application Data 3. 7. 308: (60) Provisional application No. 61/034,122, filed on Mar. A638/02 (2006.01) 5, 2008, provisional application No. 61/079,768, filed A6IP35/00 (2006.01) on Jul. 10, 2008, provisional application No. 61/086, A6IPI/00 (2006.01) 437, filed on Aug. 5, 2008, provisional application No. B65D 69/00 (2006.01) 61/144,121, filed on Jan. 12, 2009. (52) U.S. Cl. ...................... 424/133.1: 514/423: 514/165; 514/567; 514/568: 514/411; 514/570; 514/420; Publication Classification 514/413: 514/226.5: 514/682: 514/569; 514/374; (51) Int. Cl. si...","...si...S. St. E. 30: 424/141.1; 514/19.3: 514/266.4: 514/252.18: A6 IK3I/60 (2006.01) 514/234.5; 514/.414: 514/252.19; 514/275; A6 IK3I/I96 (2006.01) 514/323: 514/64; 514/456; 514/437; 514/449; A6 IK3I/92 (2006.01) 514/365: 514/266.24; 514/285; 424/649;
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Easy and Efficient Selenocyanation of Imidazoheterocycles Using Triselenodicyanide
    Easy and efficient selenocyanation of imidazoheterocycles using triselenodicyanide Sébastien Redon, Anne Roly Obah Kosso, Julie Broggi, Patrice Vanelle To cite this version: Sébastien Redon, Anne Roly Obah Kosso, Julie Broggi, Patrice Vanelle. Easy and efficient selenocya- nation of imidazoheterocycles using triselenodicyanide. Tetrahedron Letters, Elsevier, 2017, 58 (28), pp.2771-2773. 10.1016/j.tetlet.2017.06.003. hal-01665068 HAL Id: hal-01665068 https://hal.archives-ouvertes.fr/hal-01665068 Submitted on 4 Jan 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Easy and efficient selenocyanation of imidazoheterocycles using triselenodicyanide Sébastien Redon,* Anne Roly Obah Kosso, Julie Broggi and Patrice Vanelle ∗ Aix Marseille Univ, CNRS, ICR Institut de Chimie Radicalaire, UMR 7273, Equipe Pharmaco-Chimie Radicalaire (LPCR), Faculté de Pharmacie, 27 Bd Jean Moulin CS–30064 13385 Marseille Cedex5, France ARTICLE INFO ABSTRACT Article history: The regioselective selenocyanation of imidazoheterocycles using triselenodicyanide at room Received temperature is reported. The electrophilic aromatic substitution of a broad range of substrates is Received in revised form promoted by the triselenodicyanide obtained by oxidative coupling of malononitrile and Accepted selenium dioxide, under an air atmosphere. The major advantages of the presented method are Available online an easy set-up, excellent yields, short reaction times, use of odorless and inexpensive reagents and easy purification of the final products.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Genomics and Proteomics Studies of Zolpidem
    g in Geno nin m i ic M s ta & a P D r f o Journal of Heidari A, J Data Mining Genomics & Proteomics o t e l o a m n r i 2016, 7:3 c u s o J DOI: 10.4172/2153-0602.1000e125 ISSN: 2153-0602 Data Mining in Genomics & Proteomics Editorial Open Access Genomics and Proteomics Studies of Zolpidem, Necopidem, Alpidem, Saripidem, Miroprofen, Zolimidine, Olprinone and Abafungin as Anti- T umor, Peptide Antibiotics, Antiviral and Central Nervous System (CNS) Drugs A Heidari * Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA *Corresponding author: A Heidari, Faculty of Chemistry, California South University (CSU), 14731 Comet St. Irvine, CA 92604, USA, E-mail: [email protected] Received date: July 01, 2016; Accepted date: July 04, 2016; Published date: July 06, 2016 Copyright: © 2016 Heidari A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Editorial Olprinone and Abafungin based amino acids, peptide antibiotics and so on. Zolpidem, Necopidem, Alpidem, Saripidem, Miroprofen, Zolimidine, Olprinone and Abafungin (Figure 1) have severed as rich sources of variety of medicinal, pharmaceutical, anti-tumor, antibiotics and antiviral drugs (Figure 2) and biological properties [1-18]. These compounds represent an important class of Nitrogen, Oxygen, Phosphorus and Sulfur heterocyclic and they constitute useful intermediates in organic synthesis [19-39]. Zolpidem, Necopidem, Alpidem, Saripidem, Miroprofen, Zolimidine, Olprinone and Abafungin have proven to be very versatile reagents for heterocyclization and many diverse products can be prepared from the addition of these compounds to Nitrogen, Oxygen, Phosphorus and Sulfur containing compounds.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]